CDKN2A and meningioma: While the presence of CDKN2A loss is gaining increasing recognition as a key diagnostic and prognostic marker in gliomas and meningiomas, and is an inclusion criterion for some clinical trials, its molecular detection remains expensive, time consuming and not widely available.